Editas Medicine Inc
EDIT2.585USD
+0.145+5.94%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
216.39MCap. mercado
PérdidaP/E TTM
Más Datos de Editas Medicine Inc Compañía
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Información de la empresa
Símbolo de cotizaciónEDIT
Nombre de la empresaEditas Medicine Inc
Fecha de salida a bolsaFeb 03, 2016
Director ejecutivoDr. Gilmore O'Neill
Número de empleados246
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 03
Dirección11 Hurley St
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02141-2110
Teléfono16174019000
Sitio Webhttps://www.editasmedicine.com/
Símbolo de cotizaciónEDIT
Fecha de salida a bolsaFeb 03, 2016
Director ejecutivoDr. Gilmore O'Neill
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
17.51K
-2.48%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
Independent Director
Independent Director
--
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
17.51K
-2.48%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 7 de jun
Actualizado: sáb., 7 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
8.92%
BlackRock Institutional Trust Company, N.A.
7.26%
Morgan Stanley & Co. LLC
3.05%
Two Sigma Investments, LP
2.94%
Geode Capital Management, L.L.C.
2.32%
Other
75.50%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
8.92%
BlackRock Institutional Trust Company, N.A.
7.26%
Morgan Stanley & Co. LLC
3.05%
Two Sigma Investments, LP
2.94%
Geode Capital Management, L.L.C.
2.32%
Other
75.50%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
30.95%
Investment Advisor/Hedge Fund
12.97%
Research Firm
6.63%
Hedge Fund
5.44%
Bank and Trust
0.80%
Venture Capital
0.57%
Individual Investor
0.33%
Family Office
0.21%
Pension Fund
0.04%
Other
42.06%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
526
48.45M
57.87%
-23.30M
2025Q1
560
48.21M
57.60%
-23.68M
2024Q4
576
55.95M
67.78%
-11.28M
2024Q3
585
59.63M
72.30%
-8.64M
2024Q2
584
60.69M
73.86%
-19.13M
2024Q1
583
72.72M
88.97%
+367.05K
2023Q4
602
63.06M
77.30%
-13.98M
2023Q3
641
65.84M
80.91%
-11.78M
2023Q2
659
66.65M
82.05%
-208.12K
2023Q1
669
56.55M
82.00%
-9.39M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
7.47M
8.92%
+643.26K
+9.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.08M
7.26%
-551.77K
-8.32%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.55M
3.05%
+1.36M
+113.76%
Mar 31, 2025
Two Sigma Investments, LP
2.46M
2.94%
-841.30K
-25.45%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.94M
2.32%
+135.21K
+7.48%
Mar 31, 2025
State Street Global Advisors (US)
1.85M
2.21%
-26.11K
-1.39%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.61M
1.92%
-551.03K
-25.52%
Mar 31, 2025
UBS Asset Management (Switzerland)
1.60M
1.91%
+430.00K
+36.75%
Mar 31, 2025
BofA Global Research (US)
1.52M
1.81%
+1.08M
+250.36%
Mar 31, 2025
UBS Asset Management Switzerland AG
1.17M
1.4%
+1.17M
--
Jan 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
WisdomTree BioRevolution Fund
1.56%
Invesco NASDAQ Future Gen 200 ETF
0.58%
AXS Green Alpha ETF
0.29%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Ver más
WisdomTree BioRevolution Fund
Proporción1.56%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.58%
AXS Green Alpha ETF
Proporción0.29%
iShares Micro-Cap ETF
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
iShares Biotechnology ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
iShares Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
